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Background
Infection with human herpesvirus 8 (HHV-8), also known
as Kaposi sarcoma associated herpesvirus, is associated
with the development of primary effusion lymphoma and
Kaposi sarcoma. A transmembrane protein of HHV-8, K1,
is readily expressed in these tumors, and the expression of
K1 alone causes hyperplasia of lymph nodes and lympho-
mas in mice. The exact mechanism of how K1 causes
hyperplasia and lymphomas in K1-expressing mice is not
known. The cytoplasmic immunoreceptor tyrosine-based
activation motif (ITAM) of K1 was previously shown to be
involved in activation of nuclear factor-kappa B (NF-κB).
Moreover, we have recently shown that K1 suppresses Fas-
mediated apoptosis through its extracellular immu-
noglobulin-like domain and that K1-transfected mice sur-
vive a lethal dose of agonistic anti-Fas antibody (Jo2). We
thus hypothesized that development of hyperplasia and
lymphomas in K1-expressing mice is driven by alterations
in Fas signaling.
Results
Gross examination of thoracic and abdominal cavities of
transgenic mice with K1 expression driven by a ubiquitous
promoter, which were sacrificed at 18 months of age,
revealed enlarged cervical, mediastinal, renal, and
mesenteric lymph nodes and spleens. Peyer patches were
also enlarged and readily visible on the outer surface of
the ileum. Out of 10 K1 mice, 90 percent developed lym-
phoid hyperplasia (> 3 mm) and 60 percent developed
lymphomas, while all (26) control mice remained hyper-
plasia- and lymphoma-free. In the extreme cases, K1 mice
developed liver or mesenteric tumors (four and four out
of 10 mice, respectively). Spleens of 78 percent of K1 mice
were enlarged at 18 months and were on average 3.5 times
heavier than spleens of non-expressing control mice (332
± 200 mg versus 94 ± 26 mg, P < 0.03). Hematoxylin and
eosin staining of spleen sections showed expansion to the
periarteriolar lymphocyte sheath with disruption of nor-
mal follicular architecture. Staining of spleen sections
with anti-kappa and anti-lambda light chain antibodies
revealed the presence of monoclonal foci in three out of
three K1 mice (average six foci per single section of
spleen), but none in the four control mice. Moreover, K1
protein was expressed in about 10 percent of splenic cells
as judged from staining with anti-K1 antibody 2H5. To
test the hypothesis that expression of K1 protein in
spleens renders them resistant to Fas-mediated apoptosis,
splenic cells of 6-month-old K1 mice (n = 3) and matched
controls (n = 3) were isolated and incubated with 50 ng/
mL of agonistic anti-Fas antibody Jo2. At 12 hours of treat-
ment, only 4 ± 1 percent of splenocytes from K1 mice ver-
sus 17 ± 2 percent of control splenocytes were undergoing
apoptosis (P < 0.01). At 24 hours of treatment, the differ-
ence was even more significant (11 ± 0.6% versus 50 ±
6%, P < 0.005). Splenocytes of K1 mice were indeed more
resistant to Jo2-induced apoptosis than splenocytes from
age-matched control mice. Of mice inoculated with a
lethal dose of Jo2 antibody, three out of 12 K1 transgenic
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(30%) and 13 out of 22 control mice (60%) died (P <
0.05), further confirming the protective effect of K1
against Fas-mediated apoptosis.
Conclusion
Overall, these results confirm that K1 is associated with
lymphoid hyperplasia and lymphoma and provide a plau-
sible explanation. Interference of K1 with Fas-mediated
apoptosis disrupts the normal life cycle of lymphocytes.Page 2 of 2
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